このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

VBI Vaccines マネジメント

マネジメント基準チェック /44

VBI Vaccines'の CEO はJeff Baxterで、 May2016年に任命され、の在任期間は 8.08年です。の年間総報酬は$ 893.55Kで、 78.1%給与と21.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.071%を直接所有しており、その価値は$ 12.22K 。経営陣と取締役会の平均在任期間はそれぞれ6.8年と6.4年です。

主要情報

Jeff Baxter

最高経営責任者

US$893.5k

報酬総額

CEO給与比率	78.1%
CEO在任期間	8.3yrs
CEOの所有権	0.07%
経営陣の平均在職期間	6.9yrs
取締役会の平均在任期間	6.6yrs

経営陣の近況

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

CEO報酬分析

VBI Vaccines の収益と比較して、Jeff Baxter の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$894k	US$698k	-US$94m
Sep 30 2023	n/a	n/a	-US$115m
Jun 30 2023	n/a	n/a	-US$119m
Mar 31 2023	n/a	n/a	-US$120m
Dec 31 2022	US$2m	US$678k	-US$113m
Sep 30 2022	n/a	n/a	-US$111m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$605k	-US$70m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$2m	US$535k	-US$46m
Sep 30 2020	n/a	n/a	-US$42m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$1m	US$500k	-US$55m
Sep 30 2019	n/a	n/a	-US$63m
Jun 30 2019	n/a	n/a	-US$62m
Mar 31 2019	n/a	n/a	-US$66m
Dec 31 2018	US$1m	US$465k	-US$64m
Sep 30 2018	n/a	n/a	-US$56m
Jun 30 2018	n/a	n/a	-US$50m
Mar 31 2018	n/a	n/a	-US$43m
Dec 31 2017	US$826k	US$450k	-US$39m

報酬と市場: Jeffの総報酬 ($USD 893.55K ) は、 US市場 ($USD 693.01K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jeffの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jeff Baxter (63 yo)

8.3yrs

在職期間

US$893,547

報酬

Mr. Jeffery R. Baxter, also known as Jeff, FCMA, has been the Chief Executive Officer and President of VBI Vaccines Inc. since May 2016. Mr. Baxter has been the Chief Executive Officer and President of VBI...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jeffery Baxter	President	8.3yrs	US$893.55k	0.071% $ 571.7
Nell Beattie	CFO, Head of Corporate Development & Director	1.3yrs	データなし	0.0079% $ 64.1
David Anderson	Chief Scientific Officer	8.3yrs	US$564.56k	0.017% $ 139.3
Francisco Diaz-Mitoma	Chief Medical Officer	8.5yrs	US$549.22k	0.049% $ 395.0
Nicole Anderson	Director of Corporate Communications & Investor Relations	no data	データなし	データなし
Athena Kartsaklis	Senior VP of Finance	6.9yrs	データなし	データなし
Avi Mazaltov	Global Head of Manufacturing & GM of SciVac	7.3yrs	データなし	0.025% $ 199.3
Misha Nossov	Senior VP of Global Commercial Supply Strategy & Head of Europe	4.6yrs	データなし	データなし
T. Buckley	Senior Vice President of Business Development	4.6yrs	データなし	データなし
John Dillman	Chief Commercial Officer	2.1yrs	データなし	データなし

6.9yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: VBIVの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Jeffery Baxter	President	8.3yrs	US$893.55k	0.071% $ 571.7
Nell Beattie	CFO, Head of Corporate Development & Director	1.3yrs	データなし	0.0079% $ 64.1
Steven S. Gillis	Independent Chairperson of the Board	8.3yrs	US$194.03k	0.0098% $ 79.3
Denis Burger	Member of Scientific Advisory Board	no data	データなし	データなし
Peter Patriarca	Member of Scientific Advisory Board	6.6yrs	データなし	データなし
Stanley Plotkin	Member of Scientific Advisory Board	no data	データなし	データなし
Damian Braga	Chairperson of the Commercial Advisory Board & Independent Director	4.4yrs	US$105.18k	0% $ 0
Michel De Wilde	Independent Director and Chair of Scientific & Clinical Advisory Board	8.3yrs	US$107.68k	0.0058% $ 47.0
Blaine McKee	Independent Director	5.6yrs	US$120.18k	0% $ 0
Joanne Cordeiro	Independent Director	5.3yrs	US$127.68k	0% $ 0
Robert Pass	Member of Scientific Advisory Board	6.6yrs	データなし	データなし
Adam Finn	Member of Scientific Advisory Board	6.6yrs	データなし	データなし

6.6yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: VBIVの取締役会は経験豊富であると考えられます ( 6.4年の平均在任期間)。

VBI Vaccines マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Insufficient new directors

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

Recent updates

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

Consensus revenue estimates fall by 49%

Consensus revenue estimates fall by 49%

No longer forecast to breakeven

Price target decreased to US$6.67

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

Consensus forecasts updated

VBI Vaccines Inc. Announces Prehevbrio [Hepatitis B Vaccine (Recombinant)] Recommends by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

マネジメント基準チェック /44